Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Xianwen Zhang
Recruiting
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria
NCT07512596· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Lingfeng Min, Doctor
Not yet recruiting
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
NCT07490405· Northern Jiangsu People's Hospital· Source
Contact: Guoqing Jiang, MD
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source
Contact: Hua Wei, Doctor
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source
Contact: Hua Wei
Not yet recruiting
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479· Phase 3· The First Affiliated Hospital of Soochow University· Source
Contact: Xiaowen Tang
Recruiting
Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock
NCT07383103· Phase 4· Northern Jiangsu People's Hospital· Source
Contact: Qingquan Lyu, Master
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Lingfeng Min, Doctor
Recruiting
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
NCT07367516· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xianwen Zhang, Doctor
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis
NCT07324785· Northern Jiangsu People's Hospital· Source
Contact: Ying Zhu, Doctor's degree
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Xianwen Zhang, Site 0398
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045· Alpha Biopharma (Jiangsu) Co., Ltd.· Source
Contact: Buhai Wang Professor
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Xianwen Zhang, Doctor
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314· Capital Medical University· Source
Contact: Xiaobo Li
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· BioNTech SE· Source
Active, not recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301· Capital Medical University· Source
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531· China National Center for Cardiovascular Diseases· Source
Contact: Jing Yang
Recruiting
Effect of Thread Embedding Acupuncture on Postoperative Ileus Recovery After Colorectal Cancer Surgery: A Multicenter Randomized Controlled Trial
NCT07071987· Northern Jiangsu People's Hospital· Source
Contact: Daorong Wang
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· Phase 3· Evopoint Biosciences Inc.· Source
Contact: Yingjie zhao
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338· Phase 2· Suzhou Sanegene Bio Inc.· Source
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Xiang'an Zhao
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Buhai Wang, Site 0378
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Not yet recruiting
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
NCT06838520· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xuefei Ding
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Ling Feng Min, Doctor
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496· Phase 3· Takeda· Source
Not yet recruiting
Validation Study of Simplified Chinese Version of LOTCA Scale in the Assessment of Cognitive Impairment in Patients with Traumatic Brain Injury
NCT06850584· Nanjing Broad Biopharmaceutical Ltd.· Source
Contact: zhu heng Zhang
Not yet recruiting
Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
NCT06741501· Daorong Wang· Source
Contact: Daorong Wang, doctor
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· Phase 3· Cytokinetics· Source
Contact: Cytokinetics MD
Recruiting
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
NCT06090994· Phase 4· Fudan University· Source
Contact: Daorong Wang, PhD
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Xia Lu
Recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191· Phase 2/3· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source
Contact: Guangyu Bi
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
NCT06051513· Southeast University, China· Source
Contact: Ruiqiang Zheng
Not yet recruiting
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
NCT05860907· Phase 4· Fudan University· Source
Contact: Deyuan Fu, PhD
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332· Phase 3· Fudan University· Source
Contact: DeYuan Fu, MD
Recruiting
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
NCT05736965· Phase 2· Shanghai Tong Ren Hospital· Source
Contact: mei su
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
Multicenter Prospective Cohort of Sepsis and ARDS in China
NCT07863908· Shanghai Zhongshan Hospital· Source
Contact: Dingyu Tan, MD
Active, not recruiting
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· Phase 3· Eli Lilly and Company· Source
Recruiting
A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou
NCT05336539· Singlera Genomics Inc.· Source
Contact: Jun Liu, Master
Active, not recruiting
Long-term Efficacy and Safety Study of GV-971
NCT05181475· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source
Active, not recruiting
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147· Phase 3· Jazz Pharmaceuticals· Source
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305· Phase 4· Fudan University· Source
Contact: Deyuan Fu
Showing 50 of 55.